Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites 
German Inflation Accelerates to 2.9% in August 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Norway Core Inflation Rises to 3% in August 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Apple Unveils $1,999 Foldable iPhone Duo 
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Kioxia Rules Out SK Hynix Manufacturing Partnership 
Boeing, SPEEA Reach Tentative Four-Year Labor Deal 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Google Revamps EU Search Results to Meet DMA Rules 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Add as a preferred source on Google
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
